Modelling and simulation in the development and use of anti-cancer agents : An underused tool?

• Published in: Journal of pharmacokinetics and pharmacodynamics Vol. 31; no. 6; pp. 419 - 440
• Main Authors: ROMBOUT, Ferdinand, AARONS, Leon, VAN PEER, Achiel, KARLSSON, Mats, MAN, Anthony, MENTRE, France, NYGREN, Peter, RACINE, Amy, SCHAEFER, Hans, STEIMER, Jean-Louis, TROCONIZ, Inaki
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer 01.12.2004; Springer Nature B.V
• Subjects: Antineoplastic agents; Antineoplastic Agents - pharmacokinetics; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Cancer; Capecitabine; Chemotherapy; Clinical Trials as Topic; Computer Simulation; Deoxycytidine - analogs & derivatives; Deoxycytidine - therapeutic use; Drug Administration Schedule; Drug Design; Fluorouracil - analogs & derivatives; Humans; Medical sciences; Models, Biological; Pharmaceutical industry; Pharmacology. Drug treatments; Product Surveillance, Postmarketing; Quality of Life; Taxoids - therapeutic use; Vinblastine - analogs & derivatives; Vinblastine - therapeutic use; Antineoplastic agent; Human; Pharmacokinetic pharmacodynamic relationship; drug development; Malignant tumor; Research and development; oncology; pharmacokinetic and pharmacodynamic modelling; anti-cancer agents; Cancerology; Simulation; Development; Clinical trial; clinical trial simulation
• ISSN: 1567-567X; 1573-8744
• DOI: 10.1007/s10928-005-5910-2

To help identify the role of modelling and simulation in the development of anti-cancer agents, their main advantages and the obstacles to their rational use, an expert meeting was organized by COST B15. This manuscript presents a synthesis of views expressed at that meeting and indicates future directions. The manuscript also shows some examples where modelling and simulation have proven to be of relevant value in the drug development process for anti-cancer agents.